- Genentech, a unit of Roche Holdings AG RHHBY, and its collaborating partner AbbVie Inc ABBV have announced long-term follow-up data from two Phase 3 trials of Venclexta (venetoclax) in chronic lymphocytic leukemia (CLL). A post-hoc analysis from a Phase 3 trial in AML was also presented.
- Data will be presented at the European Hematology Association Virtual Congress.
- The four-year posthoc analysis of investigator-assessed progression-free survival (PFS) had a median follow-up of 52.4 months.
- The study indicated that the chemotherapy-free Venclexta plus Gazyva (obinutuzumab) regimen had an estimated progression-free survival (PFS) of 74.0% vs. 35.4% for Gazyva plus chlorambucil.
- The time to subsequent treatment (TTNT) was significantly longer among patients treated with the Venclexta plus Gazyva regimen versus the comparator (four-year TTNT 81.1% versus 59.9%).
- Furthermore, 30 months after the end of treatment, 26.9% of the Venclexta-treated patients still had undetectable minimal residual disease compared with 3.2% of those treated with the comparator.
- The most common serious/severe adverse events with Venclexta and Gazyva at 28 months follow-up were low white blood cell count and infections.
- The European Commission recently approved Venclyxto for newly diagnosed acute myeloid leukemia combined with a hypomethylating agent, azacitidine or decitabine.
- Price Action: ABBV shares are down 0.57% at $115.56 during the market session on the last check Friday.
- Editor's note: The first bullet has been updated to correct 'three phase 3 trials' to '2 Phase 3 trials and one post-hoc analysis.'
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
